Business
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
– Renowned investigator in microbial genomics to join Seres to advance Company’s efforts to develop novel microbiome therapeutics – – Following successful
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":"\n– Renowned investigator in microbial genomics to join Seres to advance Company’s efforts to develop novel microbiome therapeutics –\n\n– Following successful Data Safety Monitoring Board meeting in December for SER-155 Cohort 1, enrollment of Cohort 2 planned to begin in early 2023 –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser will begin serving on Seres’ Board, effective immediately.\n\n“It is an incredibly exciting time to be joining the Seres Board of Directors as the company prepares for its first potential product approval with SER-109 in recurrent C. difficile infection,” said Dr. Fraser. “In my view, the success of SER-109 bodes well for Seres’ broader pipeline of new clinical candidates using microbiome therapeutics as a novel approach for Infection Protection for medically compromised individuals and antimicrobial resistance more generally. I look forward to being a part of a company working diligently to continue to bring the promise of such microbiome therapeutics to patients.”\n\nDr. Fraser is the Director of The Institute for Genome Sciences, which she launched in 2007, at the University of Maryland School of Medicine. She also serves as a faculty member in the Departments of Medicine and Microbiology/Immunology. Prior to this, she held positions as President and Director of The Institute for Genomic Research; Chief of the Section on Molecular Neurobiology in the Laboratory of Physiologic and Pharmacologic Studies at the National Institute on Alcohol Abuse and Alcoholism; Senior Staff Fellow and Chief of the Unit of Receptor Regulation, Receptor Biochemistry and Molecular Biology at the Laboratory of Molecular and Cellular Neurobiology within the National Institutes of Health; and a Cancer Research Scientist at Roswell Park Memorial Institute.\n\nShe graduated from Rensselaer Polytechnic Institute in Troy, NY and received her Ph.D. in pharmacology from the State University of New York at Buffalo. She was elected as a member of the National Academy of Medicine in 2011 and recently concluded a term as President of the American Association for the Advancement of Science (AAAS).\n\n“I look forward to collaborating with Dr. Fraser, whose work has provided important contributions that ha...